# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001193125-26-065159
Filing Date
2026-02-24
Accepted
2026-02-24 06:30:26
Documents
13
Period of Report
2026-02-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | pvla-20260224.htm iXBRL | 8-K | 47393
2 | PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON FEBRUARY 24, 2026 | pvla-ex99_1.htm | EX-99.1 | 45850
3 | GRAPHIC | img6060170_0.jpg | GRAPHIC | 19979
4 | GRAPHIC | img6060170_1.jpg | GRAPHIC | 794380
| Complete submission text file | 0001193125-26-065159.txt |  | 1330419

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | pvla-20260224.xsd | EX-101.SCH | 26040
15 | EXTRACTED XBRL INSTANCE DOCUMENT | pvla-20260224_htm.xml | XML | 4710

Mailing Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087
Business Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Filer) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37471 | Film No.: 26667383
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)